Five-factor model personality traits in opioid dependence

Kornør, Hege; Nordvik, Hilmar
January 2007
BMC Psychiatry;2007, Vol. 7, p37
Academic Journal
Background: Personality traits may form a part of the aetiology of opioid dependence. For instance, opioid dependence may result from self-medication in emotionally unstable individuals, or from experimenting with drugs in sensation seekers. The five factor model (FFM) has obtained a central position in contemporary personality trait theory. The five factors are: Neuroticism, Extraversion, Openness to Experience, Agreeableness and Conscientiousness. Few studies have examined whether there is a distinct personality pattern associated with opioid dependence. Methods: We compared FFM personality traits in 65 opioid dependent persons (mean age 27 years, 34% females) in outpatient counselling after a minimum of 5 weeks in buprenorphine replacement therapy, with those in a non-clinical, age- and sex-matched sample selected from a national database. Personality traits were assessed by a Norwegian version of the Revised NEO Personality Inventory (NEO PI-R), a 240-item self-report questionnaire. Cohen's d effect sizes were calculated for the differences in personality trait scores. Results: The opioid-dependent sample scored higher on Neuroticism, lower on Extraversion and lower on Conscientiousness (d = -1.7, 1.2 and 1.7, respectively) than the controls. Effects sizes were small for the difference between the groups in Openness to experience scores and Agreeableness scores. Conclusion: We found differences of medium and large effect sizes between the opioid dependent group and the matched comparison group, suggesting that the personality traits of people with opioid dependence are in fact different from those of non-clinical peers.


Related Articles

  • Buprenorphine Maintenance: Office-Based Treatment with Addiction Clinic Support. Ortner, Romana; Jagsch, Reinhold; Schindler, Shird Dieter; Primorac, Andjela; Fischer, Gabriele // European Addiction Research;2004, Vol. 10 Issue 3, p105 

    Introduction: Buprenorphine has already been registered in 27 European countries for maintenance therapy in opioid-dependent patients. In our office-based prescription study we applied sublingual buprenorphine, initiating the treatment at the addiction clinic with subsequent treatment at the...

  • DRUG ADDICTION IN ITS RELATION TO EXTROVERSION, AMBIVERSION, AND INTROVERSION. Brown, Ralph R. // Journal of Applied Psychology;Oct35, Vol. 19 Issue 5, p555 

    This article discusses a study of the relations of drug addiction to extroversion, ambiversion, and introversion. This study consists of one hundred sixty-two morphine addicts. Most of the subjects had been withdrawn from morphine while in jail awaiting transfer to the institution, although a...

  • Buprenorphine-Containing Treatments: Place in the Management of Opioid Addiction. Robinson, Susan E. // CNS Drugs;2006, Vol. 20 Issue 9, p697 

    Although the synthetic opioid buprenorphine has been available clinically for almost 30 years, its use has only recently become much more widespread for the treatment of opioid addiction.The pharmacodynamic and pharmacokinetic profiles of buprenorphine make it unique in the armamentarium of...

  • Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependencey. Orman, Jennifer S.; Keating, Gillian M. // CNS Drugs;2009, Vol. 23 Issue 10, p899 

    Buprenorphine/naloxone (Suboxone®) comprises the partial m-opioid receptor agonist buprenorphine in combination with the opioid antagonist naloxone in a 4 : 1 ratio. When buprenorphine/naloxone is taken sublingually as prescribed, the naloxone exerts no clinically significant effect, leaving...

  • Buprenorphine: Effective Treatment of Opioid Addiction Starts in the Office. Fiellin, David A. // American Family Physician;5/1/2006, Vol. 73 Issue 9, p1513 

    Comments on the use of buprenorphine or buprenorphine/naloxone as effective office-based treatments for opioid addiction. Problem associated with prescription opioid use and dependence; Impact of opioid addiction on a person's lifestyle; Significance of the Drug Addiction Treatment Act of 2000...

  • Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review. Yokell, Michael A.; Zaller, Nickolas D.; Green, Traci C.; Rich, Josiah D. // Current Drug Abuse Reviews;Mar2011, Vol. 4 Issue 1, p28 

    The diversion, misuse, and non-medically supervised use of buprenorphine and buprenorphine/naloxone by opioid users are reviewed. Buprenorphine and buprenorphine/naloxone are used globally as opioid analgesics and in the treatment of opioid dependency. Diversion of buprenorphine and...

  • Adherence to Buprenorphine Maintenance Treatment in Opioid Dependence Syndrome: A Case Control Study. Bandawar, Mrunal; Kandasamy, Arun; Chand, Prabhat; Murthy, Pratima; Benegal, Vivek // Indian Journal of Psychological Medicine;Jul-Sep2015, Vol. 37 Issue 3, p330 

    Background: Opioid Use disorders are emerging as a serious public health concern in India. Opioid substitution treatment is one of the emerging forms of treatment in this population which needs more evidence to increase its availability and address prejudices towards the same. Materials and...

  • Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial. Molfenter, Todd; Jee-Seon Kim; Quanbeck, Andrew; Patel-Porter, Terry; Starr, Sandy; McCarty, Dennis // Implementation Science;2013, Vol. 8 Issue 1, p1 

    Background: More effective methods are needed to implement evidence-based findings into practice. The Advancing Recovery Framework offers a multi-level approach to evidence-based practice implementation by aligning purchasing and regulatory policies at the payer level with organizational change...

  • Intravenous Misuse of Buprenorphine: Characteristics and Extent Among Patients Undergoing Drug Maintenance Therapy. Moratti, Enrico; Kashanpour, Hamid; Lombardelli, Tiziana; Maisto, Maria // Clinical Drug Investigation;2010 Supplement 1, Vol. 30, p3 

    Background and objective Sublingual buprenorphine [Subutex®] is used to treat opioid dependence. However, illicit intravenous (IV) injection of buprenorphine is a widespread problem. This survey investigated the IV misuse of buprenorphine among patients receiving drug replacement therapy at...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics